Cabozantinib + Tecentriq Effective for Liver Cancer?
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
On July 4, 2022, R.K. Kelley and colleagues from the UCSF Helen Diller Family Comprehensive Cancer Center published the results of the COSMIC-312 Phase III clinical trial in the medical journal "The Lancet Oncology." The study evaluated the effectiveness and safety of Cabozantinib + Tecentriq as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC).
COSMIC-312 was an open-label, multicenter Phase III trial that randomized 837 patients with advanced HCC in a 2:1:1 ratio into three groups: Cabozantinib (40mg once daily) + Tecentriq (1200mg every three weeks) (N=432), sorafenib (400mg twice daily) (N=217), and Cabozantinib monotherapy (60mg once daily) (N=188). The primary endpoints were progression-free survival (PFS) and overall survival (OS).
With a median follow-up of 15.8 months, the median progression-free survival was 6.8 months for the Cabozantinib + Tecentriq group versus 4.2 months for the sorafenib group. The median overall survival was 15.4 months for the Cabozantinib + Tecentriq group compared to 15.5 months for the sorafenib group.
Regarding safety, the incidence of Grade 3-4 side effects included: elevated ALT (Cabozantinib + Tecentriq 9%; sorafenib 3%; Cabozantinib 6%), hypertension (Cabozantinib + Tecentriq 9%; sorafenib 8%; Cabozantinib 12%), elevated AST (Cabozantinib + Tecentriq 9%; sorafenib 4%; Cabozantinib 10%), and hand-foot syndrome (Cabozantinib + Tecentriq 8%; sorafenib 8%; Cabozantinib 9%).
The incidence of serious side effects was 18% in the Cabozantinib + Tecentriq group, 8% in the sorafenib group, and 13% in the Cabozantinib group. Grade 5 adverse events occurred in 1% of patients in the combination group and in less than 1% of patients in both the sorafenib and Cabozantinib monotherapy groups.
Based on the results of the COSMIC-312 trial, R.K. Kelley and others stated that Cabozantinib + Tecentriq as a first-line treatment shows promise as a new therapeutic option for patients with advanced HCC, although additional trials are needed.
Sources: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00326-6/fulltext
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4